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EVOLUTION OF NEUROIMAGING TECHNOLOGY
IN THE MODERN ERA
Robert H. Paul
Missouri Institute of Mental Health and Department of Psychology,
University of Missouri – Saint Louis, St. Louis, MO, USA
Clinical applications in brain science have progressed at a glacial pace when compared to other
medical disciplines. Treatments for most neurodegenerative brain diseases are limited, and cure
strategies remain underdeveloped. Pressure to improve clinical outcomes in the neurological
sciences is exacerbated by an aging population at risk for degenerative brain diseases. Fortunately,
technical advances in the field of neuroimaging offer new promise, with enhanced characterization of microstructural anatomy, network connectivity, and functional biomarkers of health
and disease. Articles highlighted in this issue describe cutting-edge applications targeting these
outcomes using diffusion tensor imaging, diffusion-based tractography, and positron emission
tomography. Finally, the glymphatic system is reviewed as a target for future neuroimaging
investigation in clinical populations such as those with Alzheimer’s disease. Integration of these
methods with new advances in computational science will inform mechanisms of healthy and
dysfunctional brain mechanisms and ideally lead to new targeted therapeutic interventions.
Key words: Neuroimaging; Alzheimer’s disease; Aging

The human brain remains one of the most puzzling mysteries in the known universe. Encased in
bone and vulnerable to slight homeostatic disruption,
the brain is not easily examined by observational
methods or invasive experimental procedures. Early
perspectives of basic structure-function relationships
were informed by clinical evaluation of individuals
who had survived traumatic brain injury, such as Mr.
Phineas Gage (3). However, the resulting models of
brain organization and physiology were incomplete
due to heterogeneity in lesion location and severity across individuals and limited capacity to measure the impact of focal lesions on larger networks
described in histopathological studies. New technical
insights were needed to bridge the science from his-

topathological bench work to in vivo examinations of
complex human behavior. The requisite technology
in brain science would not be available for nearly a
century after the clinical description of Mr. Gage.
By contrast, progress in the prevention, diagnosis,
and treatment of diseases peripheral to the central
nervous system (CNS) progressed steadily over this
time period, with more rapid advances after the mid1900s. Cardiovascular and cerebrovascular diseases
previously known as fatal became manageable for
many individuals with medications, surgery, and/or
changes in lifestyle factors related to disease onset
and progression (e.g., smoking, obesity). Similar
breakthroughs in the prevention and treatment of
other disease areas (e.g., diabetes) eclipsed the pace
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of discovery in brain science. The discrepancy in
treatment options for conditions above vs. below the
neck contributed to a growing population of adults
living longer lifespans, including a growing number
of individuals with age-associated neurodegenerative
diseases (8). The limited treatment options for the
projected expansion of adults with neurodegenerative diseases of the brain such as Alzheimer’s disease,
growing healthcare costs, and increasing numbers of
uninsured individuals all pointed towards an emerging health crisis.
Political pressure culminated in a Presidential
proclamation signed in 1989 declaring the period
from 1990-1999 as the “Decade of the Brain” (5).
The initiative targeted 14 areas in the neurological
sciences primed for breakthroughs in prevention,
treatment, and cures for the most vexing and common neurological conditions. The Decade ended
with few treatments and no interventions capable
of reversing or halting common forms of neurodegenerative diseases, such as Alzheimer’s disease,
Parkinson’s disease, or vascular dementia. However,
innovative work in the field of neural bioinformatics
and neuroimaging flourished during this period, and
enthusiasm was high that neuroimaging technology
seeded during the 1990s would significantly alter the
cadence of brain science outcomes in the near future
(10). This prediction proved accurate as borne out
through subsequent research that leveraged a historical foundation in magnetic resonance imaging
(MRI).
Early MRI systems introduced in the 1970s provided researchers and clinicians with vastly improved
spatial resolution of brain anatomy compared to
radiographic methods of the past. High field MRI
using 1.5 Tesla (15,000 Gauss) became common in
both research and clinical settings, followed by the
introduction of 3 Tesla systems. The image resolution
of 3 Tesla MRI is approximately 16 times that of 1.5
Tesla systems, allowing for significantly improved
signal-to-noise ratio and improved anatomical detail.
Eventually, 4 Tesla and even 7 Tesla systems were
introduced at select research centers, the latter providing a magnetic field 140,000 times that of earth’s
gravitational force. The improvements in image acquisition at higher field strengths combined with robust

post-processing algorithms improved visualization
of both healthy and pathological brain tissue (11).
Anatomical detail provided by high field MRI
opened a new world of brain structure-function relationships supported by the demarcation of tissue
classification into cortical gray matter, subcortical
white matter, and subcortical gray matter. Volumes
of brain regions (e.g., frontal lobe) and specific nuclei
(e.g., caudate nucleus) could be readily quantified
and contrasted between patient groups and healthy
controls or analyzed within groups to determine the
degree of shared variance between brain volumes
and measures of cognition, personality, or emotion.
Landmark studies revealed reduced hippocampal
volume in the earliest stages of Alzheimer’s disease (6),
microvascular infarcts in subcortical white matter (2),
as well as numerous other clinically relevant findings.
However, the focus on specific nuclei and regional
lobes belied the anatomical complexity of the brain
previously characterized in histological studies. Work
dating back to Golgi and Cajal (1) brilliantly revealed
the multiplex architecture of neural networks using
relatively crude methods in the 1800s, yet modern
neuroimaging studies restricted analyses to focal
brain regions. In effect, the field defaulted to a digitized version of phrenology, ascribing complex and
diverse human behaviors to isolated brain volumes.
New technology was needed to measure brain network integrity on a larger scale.
The introduction of diffusion tensor imaging
(DTI) opened a new technical portal away from the
hyper-focused regionalization of volumetric studies.
DTI measures the rate and direction of water flow (i.e.,
hydrogen) in the brain, both of which are altered by
neuronal damage (9). Common DTI outputs include
scalar metrics of water diffusion, such as fractional
anisotropy, mean diffusivity, axial diffusivity, and
radial diffusivity (see Baker et al. in this issue for
review). Refinement of DTI pulse sequences during
the Decade of the Brain allowed researchers to visualize network connections by measuring the curvature
of the diffusion metrics along known anatomical fasciculi. For the first time, the structural integrity of the
brain (later referred to as the connectome) (12) could
be defined. Subsequent studies developed methods
to quantify the integrity of brain white matter tracts
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identified using specialized processing methods
for DTI outcomes. One such method, quantified
fiber bundle length, is described in the current issue
by Zhang. Compelling evidence demonstrates the
sensitivity of quantified fiber bundle length to perturbations in cognition and to genetic risk alleles
associated with reduced brain integrity (see Baker
et al. in this issue). Technical improvements to DTI
applications continue to develop, including advances
in pulse sequences and post-processing data computations. In the current issue of this journal, Salminen
et al. describe a method to improve the DTI signal
by suppressing artifact generated by cerebrospinal
fluid (CSF). Application of this CSF-suppression
method offers improved anatomical precision of
DTI-informed network models and more robust
characterization of the scalar indices.
A notable limitation of both structural MRI and
DTI is the absence of direct functional information
about the brain. Functional information is most
commonly derived from functional MRI (fMRI)
or positron emission tomography (PET). fMRI was
introduced in the early part of the Decade of the Brain
at the Society for Magnetic Resonance in Medicine
annual meeting in 1991. The fMRI signal is generated
by changes in the blood deoxyhemoglobin concentration associated with cognitive activity completed by
the individual while inside the MR unit. The spatial
resolution of fMRI for cortical functions is quite good,
but poor temporal resolution and high data processing demands have restricted widespread adoption in
clinical settings.
By contrast, PET has long been the workhorse of
clinical functional brain imaging. PET is capable of
detecting functional properties of the brain at the
level of proteins or brain regions depending on the
selection of isotopes or ligands. The degree of anatomical specificity provided by PET represents an
advantage over fMRI. Ligands are available for specific neurotransmitters (e.g., dopamine) and specific
proteins, such as amyloid. In this issue, Cohen reviews
the research and clinical relevance of Pittsburgh
Compound-B (PiB), a PET ligand that selectively
binds to the amyloid plaques characteristic of neuropathology related to Alzheimer’s disease (13). PiB
imaging is at the forefront of modern neuroimaging
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innovation, supported by evidence of abnormal PiB
amyloid binding among older individuals at risk for
future diagnosis of Alzheimer’s disease (reviewed by
Cohen).
In addition to serving as markers of disease
mechanisms, neuroimaging tools are sensitive to
changes in brain integrity following treatment. Tate
et al. review evidence of changes in PET, fMRI, and
DTI indices following neuromodulation methods.
PET imaging targeting the dopamine system reveals
a potential mechanism of action of repetitive transcranial magnetic stimulation, and DTI studies reveal
improvement in fractional anisotropy in the brain
ipsilateral to the treated hemisphere (as reviewed
by Tate et al.). Additional randomized clinical trials
are required to define the efficacy of neuromodulation and the impact of treatment on brain network
function, yet the innovative methods represent an
intriguing non-pharmacological approach or adjuvant treatment to maximize current pharmacological
interventions.
This special issue of Technology and Innovation
concludes with a contribution from Huffman et al.
introducing a new frontier in imaging with high
research and clinical relevance. The glymphatic
and perivascular waste clearance systems identified
recently in the brain have sparked both controversy
and innovation (7). Once considered anatomically
distinct from the periphery, the CNS is linked to
the periphery through pathways that facilitate clearance of waste products across the blood-brain-barrier
(BBB) (7). As reviewed by Huffman et al., identification of these pathways has opened a new world of
discovery regarding communication between the
CSF and plasma. Neuroimaging methods applied to
animal models reveal waste products from metabolic
functions and break-down of amyloid clear the CNS
through these pathways, and, therefore, damage to
this system may play a pivotal role in the pathogenesis
of neurodegenerative diseases such as Alzheimer’s
disease. Unfortunately, neuroimaging methods to
examine this system are currently limited to animal studies. New innovation is required to translate
these methods to human application and successfully
define the relevance of disturbed glymphatic flow
dynamics to human brain models.
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The primary governor of progress in brain science is the extraordinary complexity of the brain.
Comprised of a dizzying number of interconnections,
the brain is estimated to include as many as 1011 x 1014
synapses. Until recently, the computational methods
required to capture the structural and functional complexity of the human brain in vivo were non-existent.
Neuroimaging technology now permits microscopic
analyses and visualization of complete tracts and
systems. Functional neuroimaging methods using
biologically-specific ligands such as PiB reliably identify individuals at risk for developing dementia, with
new advances coming from ligands for tau and other
neuropathological markers of disease. Finally, it is
likely that future models of brain structure-function
will incorporate waste clearance dynamics occurring
through central-peripheral exchange. Once established, treatment (e.g., neuromodulation) and cure
strategies can be strategically targeted against specific
mechanisms of brain dysfunction.
Ambitious initiatives are underway to define the
human brain connectome (12). Detailed mapping
of brain circuitry provided from the connectome
project will set a new water mark, with an emphasis
on complete and integrated brain circuits. Delineation
of brain phenotypes and endophenotypes will emerge
from the integration of multiple imaging modalities,
such as DTI/diffusion spectrum imaging and resting state fMRI. The neuroimaging field has already
shifted in this new direction (4). The rich outcomes
generated from these studies are critical to develop
cost-effective options for personalized medicine
and optimal patient outcomes. Undoubtedly, progress will be governed by the pace of innovation in
computational science and federal funding for new
research. A new political stage was set in April of
2013, with President Obama announcing the launch
of the BRAIN Initiative with coordinated funding
from multiple federal sources to support interdisciplinary and highly integrated brain science research.
Time will determine whether the new initiative is
sufficiently funded to support the development of
treatments that can arrest and/or reverse neurological disease. There is little doubt, however, that the
neuroimaging technology described in this issue will
play a role in this next wave of strategic brain science
aimed at improving the lives of individuals affected
by a neurological illness worldwide.
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